Novel Substituted Benzimidazole Dosage Forms and Method of Using Same
AssigneeThe Curators of the University of Missouri
InventorJeffrey O. Phillips
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical composition consisting of a proton pump inhibitor, including preparations of s-omeprazole, and at least one buffering agent. Also provided is a pharmaceutical composition comprising a parietal cell activator, an anti-foaming agent, a flavoring agent and combinations thereof; a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical composition; and a kit for the preparation of a liquid oral pharmaceutical composition. Dosage forms include: liquid, powder, tablet, capsule, effervescent powder, effervescent tablet, pellets, and granules
Claims28
1-22. (canceled)
A method for treating an acid-caused gastrointestinal disorder comprising the step of administering to a subject suffering from said disorder a solid pharmaceutical composition comprising:
- (a) about 10 mg to about 40 mg of s-omeprazole or a pharmaceutically acceptable salt thereof, wherein the s-omeprazole is non-enteric coated;
- and
- (b) sodium bicarbonate in an amount of about 0.2 mEq to about 5 mEq per 2 mg of the s-omeprazole or a pharmaceutically acceptable salt thereof;
- wherein the composition contains no sucralfate, the acid-caused gastrointestinal disorder is selected from the group consisting of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and erosive esophagitis, and the sodium bicarbonate is present in the composition in an amount sufficient to substantially prevent or inhibit acid degradation of at least some of the s-omeprazole by gastric acid upon administration to the subject.
Dependencies are inferred from the claim text.